



REGULATED INFORMATION • REGULATED INFORMATION • REGULATED INFORMATION

## HALF YEAR REPORT ON THE LIQUIDITY CONTRACT

**Paris and Boston, July 27, 2017 - Neovacs (Alternext Paris : ALNEV)** releases its six-monthly report on the liquidity contract signed with Invest Securities.

The liquidity account had the following holdings as of June 30, 2017:

- 131,934 shares
- € 390,277.09

For the prior (December 31, 2016), the corresponding figures were:

- 394 422 shares
- 134 790,14€

### **About Neovacs**

Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN $\alpha$  Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology, allergies and Type 1 diabetes. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. [www.neovacs.fr](http://www.neovacs.fr)

### **Contacts**

#### **Contacts**

**NEOVACS – Corporate Communication & Investor Relations**

**Charlène Masson**

+33 (0)1 53 10 93 14

[cmasson@neovacs.com](mailto:cmasson@neovacs.com)

**LIFESCI ADVISORS- Investor Relations / Financial Communications**

**Chris Maggos**

+41 79 367 6254

[chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)